AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury

Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury Orphan Drug Designation is given to a drug or biologic for the treatment, diagnosis or prevention of a rare ... Biopharmaceuticals, Neurology, FDA AbbVie, elezanumab, spinal cord injury
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news